NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communicatio...(he treatment ofdiabetes the regulation o...)

Date:2/29/2008

he treatment of diabetes, the regulation of lipid metabolism and bone metabolism and repair. The company's lead compounds are (1) NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer; (2) NRX5183, a RAR alpha subtype- specific agonist for the treatment of acute leukemia; and (3) NRX4310, a function selective receptor modulator for the treatment and prevention of chemotherapy-induced neutropenia. Located in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-looking statements.

CONTACTS: Media

David Sch
'/>"/>

SOURCE NuRx Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
2. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
3. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
6. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
7. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
8. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
9. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
10. JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM)
11. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors